-13.0%
CTSH vs MRNA
+485.7%
-498.8%
-54.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.9% | +5.4% | -2.5% | +2.7% |
| 7D | -3.7% | -1.1% | -2.6% | -3.7% |
| 30D | +3.7% | +126.1% | -122.4% | -1.2% |
| 3M | +17.9% | +190.0% | -172.1% | +10.9% |
| 6M | -2.6% | +157.2% | -159.9% | -7.6% |
| YTD | -26.4% | +388.2% | -414.6% | -34.5% |
| 1Y | -13.0% | +467.0% | -480.1% | -24.5% |
| All | -13.0% | +485.7% | -498.8% | -24.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling